The deal’s purpose is primarily to acquire talent, aka an acqui-hire, adding nine key Cleanlab employees to Handshake’s ...

Eclipsebio Acquires Terrain Bio to Expand Its End-to-End AI Platform for the Design, Manufacturing, and Validation of RNA Therapeutics ...

One way leads to a future in which AI-driven breakthroughs remain the exclusive domain of pharmaceutical giants with billion-dollar budgets. The other, to a landscape where breakthroughs regularly ...

Converge Bio, the AI platform for accelerated drug discovery and development, announced today $25 million in Series A funding, bringing its total raised to $30 million. The round was led by Bessemer ...

Jan 6 (Reuters) - Variant Bio, a private biotech firm, said on Tuesday it has launched a platform that uses artificial intelligence on genetic data to discover new drug candidates to send into human ...

Artificial intelligence is moving quickly into drug discovery as pharmaceutical and biotech companies look for ways to cut years off R&D timelines and increase the chances of success amid rising costs ...

Jan 6 (Reuters) - Variant Bio, a private biotech firm, said on Tuesday it has launched a platform that uses artificial intelligence on genetic data to discover new ‌drug candidates to send into human ...

ESMO AI & Digital Health 2025 - Massive Bio today introduced Reticulum Nexus, the company's most significant technological leap to date: a patient-centric, multi-agent platform engineered to ...

Artificial intelligence (AI) is edging closer to the bioreactor. But its progress is being slowed by an unglamorous obstacle: the disarray of bioprocessing data. According to Phil Mounteney, vice ...

YD Bio Limited ('YD Bio” or the 'Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the ...